immunotherapy - search results
If you're not happy with the results, please do another search
Cancer Immunotherapy Expansion Using a New Predictive Biomarker
In this Inside Precision Medicine webinar, our distinguished guest speaker, Dr. Scott Tomlins, will describe the development, validation, and clinical utility of a new pan-tumor predictive biomarker for immunotherapy benefit: Immunotherapy Response Score™ (IRS).
Blocking T-Cell Migration with Immunotherapy Slows Melanoma Growth
Using a chemical blocker stops CD8+ T cells from migrating out of skin cancer cells. Together with immunotherapy, this new approach could boost the efficacy of immunotherapy.
Immunotherapy Response Affected by CD5+ Cells
CD5+ cells could be an important marker for response to immunotherapy for melanoma and other cancers, according to new research from the Washington University School of Medicine.
New Insights to Poor Lung Cancer Response to Immunotherapy
Bacteria naturally found in the lungs help create an environment that suppresses T-cell activation in the lymph nodes near the lungs—a finding that could explain why immunotherapy for lung cancer often fails.
Persistent Mutations in Tumors May Predict Response to Immunotherapy
New evidence from researchers at the Johns Hopkins Kimmel Cancer Center has found that a subset of mutations within the TMB—defined at “persistent mutations"—are less likely than others to be edited out, making them always visible to the immune system which results in them being more likely to respond to immunotherapies.
Melanoma Immunotherapy Boosted by Sugar Found in Seaweed
L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase TILs, promote antitumor immunity, and improve the efficacy of immunotherapy.
Pre-Surgery Immunotherapy for Colorectal Cancer Proves Highly Effective
Using immune checkpoint inhibitors prior to surgery of patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) is an effective approach to treating the disease
Gilead to Purchase Remaining Rights to Potential First-in-Class Immunotherapy from Jounce Therapeutics
Gilead Sciences and Jounce Therapeutics announced late Tuesday amendments to the existing terms and licensing agreements for GS-1811 (previously called JTX-1811), a potential first-in-class anti-CCR8 antibody in development as a potential treatment against solid tumors.
Reducing Hypoxia May Improve Immunotherapy
Tired T cells not only lose their own ability to fight cancer; they also influence surrounding cells to suppress an immune response.
Qu Biologics Taps Karolinska Institute to Validate Qu’s Immunotherapy Platform
The research will be led by Prof. Jonas Fuxe, and will characterize the molecular targets of Qu's Site Specific Immunomodulator (SSI) therapy at the tissue level that lead to resolution of disease.